Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer
Status:
Terminated
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Chemoembolization kills tumor cells by carrying drugs directly into the tumor and blocking
the blood flow to the tumor. Everolimus may stop the growth of tumor cells by blocking some
of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet
known whether transarterial chemoembolization with doxorubicin is more effective when given
alone or when given together with everolimus in treating patients with liver cancer.
PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of
everolimus when given together with transarterial chemoembolization with doxorubicin and to
see how well it works compared with giving transarterial chemoembolization with doxorubicin
alone in treating patients with liver cancer.